Epi-croomine and croomine from Stemona tuberosa antimalarial drug for inhibiting dihydrofolate reductase (DHFR) activity and their molecular modeling

Authors

Pratiwi Pudjiastuti, Airlangga University
Sri Sumarsih, Airlangga University
Heny Arwati, Airlangga University
Ilma Amalina, Airlangga University
Much Z. Fanani, Airlangga University
Edi P. Utomo, Brawijaya University
Loeki E. Fitri, Brawijaya University
Ari Satia Nugraha, University of WollongongFollow
Wilford Lie, University of WollongongFollow
Stephen G. Pyne, University of WollongongFollow

RIS ID

91737

Publication Details

Pudjiastuti, P., Sumarsih, S., Arwati, H., Amalina, I., Fanani, M. Z., Utomo, E. P., Fitri, L., Nugraha, A. S., Lie, W. & Pyne, S. G. (2014). Epi-croomine and croomine from Stemona tuberosa antimalarial drug for inhibiting dihydrofolate reductase (DHFR) activity and their molecular modeling. Journal of Chemical and Pharmaceutical Research, 6 (6), 544-548.

Abstract

One of the mechanism actions of antimalarial drugsis by an inhibiting on the enzyme dihydrofolate reductase (DHFR), an enzyme target antifolate drug. Epi-croomine and croomine, are alkaloids isolated from Stemonatuberosa showed DHFR inhibition with Ki of 61.14 and 100.59 μM and KM values of30.68 and 27.06 μM at 10 ppm. The IC50 to the DHFR of croomine and pyrimethamine were 5.29 and 7.71 μM, respectively. Tuberostemonine is not active to the enzyme. The kinetic analysis showed that both epi-croomine and croomine competitively inhibited to the human DHFR recombinant. The molecular modeling of the compounds to the human DHFR was estimate depi-croomine and croomine's binding free energy of -6.66 and -7.60 kcal/mol. The docking showed that both epi-croomine and croomine could possibly form hydrogen bonds with the amino acid residue of theAla9, which residues on the active site of the enzyme.